SEC Form 4 · accession 0000899243-19-002141
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas DesRosier
Officer — Chief Legal Officer and EVP
Period of report
Jan 25, 2019
Accepted (ET)
Jan 29, 2019 · 6:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1 | Jan 26, 2019 | M | 15,000 | — | A | 21,525 | D | |
| COMMON STOCKF2 | Jan 28, 2019 | S | 5,471 | $5.7536 | D | 16,054 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY)F3 | $6.01 | Jan 25, 2019 | A | 84,800 | A | — | Jan 24, 2029 | Common Stock | 84,800 | 84,800 | D |
| RESTRICTED STOCK UNITSF1,F4 | — | Jan 26, 2019 | M | 15,000 | D | — | — | Common Stock | 15,000 | 25,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $5.75 to $5.8435. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The option will vest as to 25% of the shares on January 25, 2020. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
- F4These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020.